Kailera Therapeutics is trading 4.3% up at $18.06 as the stock participates in a broad risk-on move in U.S. equities and a rally among biotechnology peers.
- The upward move is driven by strong sector earnings and positive sentiment toward high-growth names.
- There is no fresh, stock-specific news today; the gains reflect major index advances lifting the broader industry.